Comparative Pharmacology
Head-to-head clinical analysis: CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER versus KEFLET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER versus KEFLET.
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER vs KEFLET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefotetan is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), resulting in cell lysis and death.
Keflet (warfarin) inhibits vitamin K epoxide reductase, preventing the recycling of vitamin K and thereby reducing the synthesis of clotting factors II, VII, IX, and X in the liver.
1 to 2 g intravenously every 12 hours for 5 to 10 days. For severe infections, 2 g intravenously every 12 hours.
500 mg orally every 12 hours for 10-14 days; for uncomplicated UTI: 250 mg orally every 12 hours for 7 days.
None Documented
None Documented
Terminal elimination half-life 3-4 hours in normal renal function; prolonged in renal impairment (e.g., up to 13 hours in severe renal failure).
0.5-1 hour; prolonged in renal impairment (up to 20-30 hours in ESRD).
Primarily renal (unchanged drug) ~88%; minor biliary/fecal ~6-9%.
Renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal < 5%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic